SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological therapeutic options. The beneficial effects of relaxin peptide treatment have been demonstrated previously in clinically relevant animal models of liver disease. However...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Kaftanovskaya, Elena, Ng, Hooi Hooi, Rivas, Bryan, Myhr, Courtney, Shupe, Thomas, Hu, Xin, Ferrer, Marc, Southall, Noel, Wilson, Kenneth, Marugan, Juan, Bishop, Colin, Agoulnik, Irina, Agoulnik, Alexander
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Non-Steroid Hormone Signaling
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados